U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H27FN2O4
Molecular Weight 426.4815
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ILOPERIDONE

SMILES

CC(=O)c1ccc(c(c1)OC)OCCCN2CCC(CC2)c3c4ccc(cc4on3)F

InChI

InChIKey=XMXHEBAFVSFQEX-UHFFFAOYSA-N
InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022192s015lbl.pdf

Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia. Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for α adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NEα1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors. Iloperidone is indicated for the treatment of acute schizophrenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
110.0 nM [IC50]
0.4 nM [IC50]
210.0 nM [IC50]
0.4 nM [IC50]
161.0 nM [IC50]
0.011 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FANAPT

Approved Use

FANAPT is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.

Launch Date

1.24148161E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.79 ng/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
29.4 ng × h/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
17.6 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3%
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ILOPERIDONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
32 mg 1 times / day multiple, oral
MTD
Dose: 32 mg, 1 times / day
Route: oral
Route: multiple
Dose: 32 mg, 1 times / day
Sources:
unhealthy, 18 - 55
n = 24
Health Status: unhealthy
Condition: Schizophrenia
Age Group: 18 - 55
Population Size: 24
Sources:
24 mg 1 times / day multiple, oral
Highest studied dose
Dose: 24 mg, 1 times / day
Route: oral
Route: multiple
Dose: 24 mg, 1 times / day
Sources: Page: p.3
unhealthy, 42 (13.1)
n = 31
Health Status: unhealthy
Condition: Bipolar Disorder
Age Group: 42 (13.1)
Sex: M+F
Population Size: 31
Sources: Page: p.3
438 mg multiple, oral (total)
Overdose
Dose: 438 mg
Route: oral
Route: multiple
Dose: 438 mg
Sources: Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources: Page: p.17
Other AEs: Extrapyramidal symptoms, Electrocardiogram QTc interval prolonged...
Other AEs:
Extrapyramidal symptoms
Electrocardiogram QTc interval prolonged
Sources: Page: p.17
576 mg single, oral
Overdose
Dose: 576 mg
Route: oral
Route: single
Dose: 576 mg
Sources: Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources: Page: p.17
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 874
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 874
Sources: Page: p.9
Other AEs: Somnolence...
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Other AEs: Orthostatic hypotension...
Other AEs:
Orthostatic hypotension (5%)
Sources: Page: p.7
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Other AEs: Weight gain...
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
n = 3210
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 3210
Sources: Page: p.8
Other AEs: Gynecomastia, Galactorrhea...
Other AEs:
Gynecomastia (0.1%)
Galactorrhea (0.2%)
Sources: Page: p.8
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.8
Other AEs: Hyperprolactinemia...
Other AEs:
Hyperprolactinemia (26%)
Sources: Page: p.8
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources: Page: p.7
Other AEs: Syncope...
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources: Page: p.7
Other AEs: Seizures...
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Other AEs: Leukopenia, Neutropenia...
Other AEs:
Leukopenia
Neutropenia
Agranulocytosis
Sources: Page: p.7
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.8
Other AEs: Temperature regulation disorder, Dysphagia...
Other AEs:
Temperature regulation disorder
Dysphagia
Sources: Page: p.8
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.9
Other AEs: Suicide attempt, Priapism...
Other AEs:
Suicide attempt
Priapism
Sources: Page: p.9
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.4
unhealthy
n = 160
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 160
Sources: Page: p.4
Other AEs: QT interval prolonged...
Other AEs:
QT interval prolonged
Sources: Page: p.4
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.5
Other AEs: Neuroleptic malignant syndrome...
Other AEs:
Neuroleptic malignant syndrome
Sources: Page: p.5
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.6
Other AEs: Tardive dyskinesia, Hyperglycemia...
Other AEs:
Tardive dyskinesia
Hyperglycemia
Sources: Page: p.6
AEs

AEs

AESignificanceDosePopulation
Electrocardiogram QTc interval prolonged
438 mg multiple, oral (total)
Overdose
Dose: 438 mg
Route: oral
Route: multiple
Dose: 438 mg
Sources: Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources: Page: p.17
Extrapyramidal symptoms
438 mg multiple, oral (total)
Overdose
Dose: 438 mg
Route: oral
Route: multiple
Dose: 438 mg
Sources: Page: p.17
unhealthy
n = 1
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1
Sources: Page: p.17
Somnolence 11.9%
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 874
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 874
Sources: Page: p.9
Orthostatic hypotension 5%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Weight gain 18%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Gynecomastia 0.1%
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
n = 3210
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 3210
Sources: Page: p.8
Galactorrhea 0.2%
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
n = 3210
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 3210
Sources: Page: p.8
Hyperprolactinemia 26%
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.8
Syncope 0.4%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources: Page: p.7
Seizures 0.1%
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
n = 1344
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 1344
Sources: Page: p.7
Agranulocytosis
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Leukopenia
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Neutropenia
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.7
Dysphagia
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.8
Temperature regulation disorder
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.8
Priapism
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.9
Suicide attempt
12 mg 2 times / day multiple, oral (max)
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.9
QT interval prolonged
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.4
unhealthy
n = 160
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 160
Sources: Page: p.4
Neuroleptic malignant syndrome
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.5
Hyperglycemia
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.6
Tardive dyskinesia
12 mg 2 times / day multiple, oral
Recommended
Dose: 12 mg, 2 times / day
Route: oral
Route: multiple
Dose: 12 mg, 2 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Schizophrenia
Sources: Page: p.6
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
unlikely
weak (co-administration study)
Comment: 17% increase in total exposure and a 26% increase in the maximum plasma concentrations Cmax of dextromethorphan;
Page: 16.0
unlikely
weak (co-administration study)
Comment: a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax;
Page: 16.0
weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
yes
yes (co-administration study)
Comment: administration of ketoconazole (CYP3A4 inhibitor) increased AUC of iloperidone by 57%; administration with paroxetine AND ketoconazole resulted in a 1.4 fold increase in steady-state concentration of iloperidone;
Page: 15.0
yes
yes (pharmacogenomic study)
Comment: pharmacogenic study?; administration of fluoxetine (potent inhibitor of CYP2D6) increased AUC of iloperidone by about 2- to 3-fold; administration of paroxetine (potent inhibitor of CYP2D6) increased mean steady-state peak concentrations of iloperidone by about 1.6 fold; administration with paroxetine AND ketoconazole resulted in a 1.4 fold increase in steady-state concentration of iloperidone;
Page: 15.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
1989
3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873).
1995 Mar 31
The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
1995 Sep
Iloperidone binding to human and rat dopamine and 5-HT receptors.
1996 Dec 19
Iloperidone (Hoechst Marion Roussel Inc).
1999 Jun
Treatments for chronic psychosis.
2001 Dec
Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone.
2002 Apr
Iloperidone (Novartis).
2002 Jan
New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.
2002 Jul
Gateways to clinical trials.
2002 Nov
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
2002 Nov 29
Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study.
2003
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
2003 Feb 21
Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.
2003 Sep
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
2004 Feb
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
2008 Apr
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
2008 Apr
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
2008 Apr
New advances in the treatment of schizophrenia. Introduction.
2008 Apr
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
2008 Jan
American psychiatric association.
2008 Jun
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.
2008 Mar
Gateways to clinical trials.
2008 Oct
Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.
2009 Apr
Genome-wide association studies in pharmacogenomics: untapped potential for translation.
2009 Apr 28
Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
2009 Aug
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
2009 Aug
Iloperidone: a new option for the treatment of schizophrenia.
2009 Dec
Pharmacogenomics: the promise of personalized medicine for CNS disorders.
2009 Jan
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
2009 Jun
Akathisia and second-generation antipsychotic drugs.
2009 May
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
2009 Nov
Iloperidone: in schizophrenia.
2009 Oct
Iloperidone for the treatment of schizophrenia.
2010 Aug
Iloperidone for schizophrenia.
2010 Aug
A review of new atypical antipsychotic launches in the United States.
2010 Dec
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
2010 Dec
New atypical antipsychotics for schizophrenia: iloperidone.
2010 Feb 18
Iloperidone (Fanapt)--another second-generation antipsychotic.
2010 Feb 22
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.
2010 Feb 28
Gateways to clinical trials.
2010 Jan-Feb
New drugs: asenapine, iloperidone, and bepotastine besilate.
2010 Jan-Feb
Atypical antipsychotic metabolism and excretion.
2010 Jul
Iloperidone for the treatment of schizophrenia.
2010 May
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
2010 May
The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
2010 Oct
New antipsychotic drugs: how do their receptor-binding profiles compare?
2010 Sep
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
2013 Jan
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013 Nov
Patents

Sample Use Guides

The recommended target dosage is 12 to 24 mg/day administered twice daily. This target dosage range is achieved by daily dosage adjustments, alerting patients to symptoms of orthostatic hypotension, starting at a dose of 1 mg twice daily, then moving to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg twice daily on Days 2, 3, 4, 5, 6, and 7 respectively, to reach the 12 mg/day to 24 mg/day dose range.
Route of Administration: Oral
While pacing the hearts at stimulation cycle lengths of 200 or 250 ms, or during natural sinus rhythm (no external pacing), iloperidone 100 nmol/L prolonged MAPD(90) by respectively 9.2 ± 0.9, 11.2 ± 1.6 and 21.4 ± 2.3 ms.
Name Type Language
ILOPERIDONE
DASH   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ILOPERIDONE [VANDF]
Common Name English
HP-873
Code English
ILOPERIDONE [USAN]
Common Name English
4'-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO)PROPOXY)-3'-METHOXYACETOPHENONE
Systematic Name English
ILOPERIDONE [ORANGE BOOK]
Common Name English
ILOPERIDONE [WHO-DD]
Common Name English
ILOPERIDONE [MART.]
Common Name English
HP 873
Code English
ETHANONE, 1-(4-(3-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)PROPOXY)-3-METHOXYPHENYL)-
Systematic Name English
ILOPERIDONE [INN]
Common Name English
ILOPERIDONE [USP-RS]
Common Name English
FANAPT
Brand Name English
ILOPERIDONE [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175430
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
LIVERTOX 498
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
WHO-VATC QN05AX14
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
NCI_THESAURUS C29710
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
WHO-ATC N05AX14
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
Code System Code Type Description
DRUG BANK
DB04946
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
EVMPD
SUB08135MIG
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
WIKIPEDIA
Iloperidone
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
LACTMED
Iloperidone
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
ChEMBL
CHEMBL14376
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
INN
7045
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
MERCK INDEX
M6211
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY Merck Index
USP_CATALOG
1336249
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C83784
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
EPA CompTox
133454-47-4
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
PUBCHEM
71360
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
CAS
133454-47-4
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
HSDB
8207
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
RXCUI
73178
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY RxNorm
MESH
C081732
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
FDA UNII
VPO7KJ050N
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
DRUG CENTRAL
3294
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY
IUPHAR
87
Created by admin on Sat Jun 26 00:04:24 UTC 2021 , Edited by admin on Sat Jun 26 00:04:24 UTC 2021
PRIMARY